Menopausal hormone therapy: Examining cardiovascular and clinical impacts of treatment

Future Cardiology

Volumn 9, Issue 3, 2013, Pages 427-435

  Chiu, Christine L ^a   Lind, Joanne M ^a  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

blood pressure; cardiovascular disease; coronary artery disease; estrogen; hypertension; menopausal hormone therapy; menopause; stroke

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; HORMONE; PLACEBO; PROGESTERONE; SEX HORMONE;

ARTERIAL WALL THICKNESS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY CALCIFICATION; DIASTOLIC BLOOD PRESSURE; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HEART INFARCTION; HORMONAL THERAPY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MENOPAUSAL SYNDROME; MENOPAUSE; META ANALYSIS (TOPIC); NONHUMAN; OUTCOME ASSESSMENT; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTOLIC BLOOD PRESSURE; VENOUS THROMBOEMBOLISM;

CARDIOVASCULAR DISEASES; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE;

EID: 84877853045     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.13.14     Document Type: Review

References (71)

1. Stevenson JC. A woman's journey through the reproductive, transitional and postmenopausal periods of life: impact on cardiovascular and musculo-skeletal risk and the role of estrogen replacement. Maturitas 70(2), 197-205 (2011).
2. Canderelli R, Leccesse LA, Miller NL, Unruh Davidson J. Benefits of hormone replacement therapy in postmenopausal women. J. Am. Acad. Nurse Pract. 19(12), 635-641 (2007).
3. Gavin KM, Jankowski C, Kohrt WM, Stauffer BL, Seals DR, Moreau KL. Hysterectomy is associated with large artery stiffening in estrogen-deficient postmenopausal women. Menopause 19(9), 1000-1007 (2012).
4. Freeman EW, Sherif K. Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric 10(3), 197-214 (2007).
5. Wellons M, Ouyang P, Schreiner PJ, Herrington DM, Vaidya D. Early menopause predicts future coronary heart disease and stroke: the Multi-Ethnic Study of Atherosclerosis. Menopause 19(10), 1081-1087 (2012).
6. Wildman RP, Colvin AB, Powell LH et al. Associations of endogenous sex hormones with the vasculature in menopausal women: the Study of Women's Health Across the Nation (SWAN). Menopause 15(3), 414-421 (2008).
7. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann. Intern. Med. 133(12), 933-941 (2000).
8. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288(3), 321-333 (2002).
9. Henderson BE, Paganini-Hill A, Ross RK. Estrogen replacement therapy and protection from acute myocardial infarction. Am. J. Obstet. Gynecol. 159(2), 312-317 (1988).
10. O'Keefe JH Jr, Kim SC, Hall RR, Cochran VC, Lawhorn SL, McCallister BD. Estrogen replacement therapy after coronary angioplasty in women. J. Am. Coll. Cardiol. 29(1), 1-5 (1997).
11. Biondi-Zoccai G, Romagnoli E, Agostoni P et al. Are propensity scores really superior to standard multivariable analysis? Contemp. Clin. Trials 32(5), 731-740 (2011).
12. Espeland MA, Marcovina SM, Miller V et al. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Circulation 97(10), 979-986 (1998).
13. Gurdasani D, Sjouke B, Tsimikas S et al. Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease. The EPIC-Norfolk Prospective Population Study. Arterioscler. Thromb. Vasc. Biol. 32(12), 3058-3065 (2012).
14. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 280(7), 605-613 (1998).
15. Grady D, Herrington D, Bittner V et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 288(1), 49-57 (2002).
16. Manson JE, Hsia J, Johnson KC et al. Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med. 349(6), 523-534 (2003).
17. Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291(14), 1701-1712 (2004).
18. Anderson TE, Rutledge LT, Dyer RS. Altered neuronal excitability accompanying experimental prevention of supersensitivity in undercut cortex. Brain Res. 95(1), 147-153 (1975).
19. Angerer P, Stork S, Kothny W, Schmitt P, Von Schacky C. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler. Thromb. Vasc. Biol. 21(2), 262-268 (2001).
20. Herrington DM, Reboussin DM, Brosnihan KB et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N. Engl. J. Med. 343(8), 522-529 (2000).
21. Shahar E, Burke GL, Cushman M, Heckbert SR, Ouyang P, Szklo M. Post menopausal hormones and measures of subclinical atherosclerosis: the multi-ethnic study of atherosclerosis. Prev. Med. 47(1), 38-45 (2008).
22. Yeboah J, Reboussin DM, Waters D, Kowalchuk G, Herrington DM. Effects of estrogen replacement with and without medroxyprogesterone acetate on brachial flow-mediated vasodilator responses in postmenopausal women with coronary artery disease. Am. Heart J. 153(3), 439-444 (2007).
23. Hodis HN, Mack WJ, Lobo RA et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 135(11), 939-953 (2001).
24. Manson JE, Allison MA, Rossouw JE et al. Estrogen therapy and coronary-artery calcification. N. Engl. J. Med. 356(25), 2591-2602 (2007).
25. Barrett-Connor E, Laughlin GA. Hormone therapy and coronary artery calcification in asymptomatic postmenopausal women: the Rancho Bernardo Study. Menopause 12(1), 40-48 (2005).
26. Rockman CB, Maldonado TS, Jacobowitz GR, Adelman MA, Riles TS. Hormone replacement therapy is associated with a decreased prevalence of peripheral arterial disease in postmenopausal women. Ann. Vasc. Surg. 26(3), 411-418 (2012).
27. Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J. Gen. Intern. Med. 21(4), 363-366 (2006).
28. Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst. Rev. 7, CD004143 (2012).
29. Scuteri A, Bos AJ, Brant LJ, Talbot L, Lakatta EG, Fleg JL. Hormone replacement therapy and longitudinal changes in blood pressure in postmenopausal women. Ann. Intern. Med. 135(4), 229-238 (2001).
30. Van Ittersum FJ, Van Baal WM, Kenemans P et al. Ambulatory-not office-blood pressures decline during hormone replacement therapy in healthy postmenopausal women. Am. J. Hypertens. 11(10), 1147-1152 (1998).
31. The Writing Group for the Pepi Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 273(3), 199-208 (1995).
32. Wassertheil-Smoller S, Anderson G, Psaty BM et al. Hypertension and its treatment in postmenopausal women: baseline data from the Women's Health Initiative. Hypertension 36(5), 780-789 (2000).
33. Chiu CL, Lujic S, Thornton C et al. Menopausal hormone therapy is associated with having high blood pressure in postmenopausal women: observational cohort study. PLoS One 7(7), e40260 (2012).
34. Fung MM, Poddar S, Bettencourt R, Jassal SK, Barrett-Connor E. A cross-sectional and 10-year prospective study of postmenopausal estrogen therapy and blood pressure, renal function, and albuminuria: the Rancho Bernardo Study. Menopause 18(6), 629-637 (2011).
35. Karalis I, Beevers G, Beevers M, Lip G. Hormone replacement therapy and arterial blood pressure in postmenopausal women with hypertension. Blood Press. 14(1), 38-44 (2005).
36. Kornhauser C, Malacara JM, Garay ME, Perez-Luque EL. The effect of hormone replacement therapy on blood pressure and cardiovascular risk factors in menopausal women with moderate hypertension. J. Hum. Hypertens. 11(7), 405-411 (1997).
37. Kaya C, Dincer Cengiz S, Cengiz B, Akgun G. The long-term effects of low-dose 17beta-estradiol and dydrogesterone hormone replacement therapy on 24-h ambulatory blood pressure in hypertensive postmenopausal women: a 1-year randomized, prospective study. Climacteric 9(6), 437-445 (2006).
38. Bechlioulis A, Kalantaridou SN, Naka KK et al. Endothelial function, but not carotid intima-media thickness, is affected early in menopause and is associated with severity of hot flushes. J. Clin. Endocrinol. Metab. 95(3), 1199-1206 (2010).
39. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N. Engl. J. Med. 323(1), 22-27 (1990).
40. Matthews KA, Kuller LH, Sutton-Tyrrell K, Chang YF. Changes in cardiovascular risk factors during the perimenopause and postmenopause and carotid artery atherosclerosis in healthy women. Stroke 32(5), 1104-1111 (2001).
41. Lisabeth LD, Beiser AS, Brown DL, Murabito JM, Kelly-Hayes M, Wolf PA. Age at natural menopause and risk of ischemic stroke: the Framingham heart study. Stroke 40(4), 1044-1049 (2009).
42. Finucane FF, Madans JH, Bush TL, Wolf PH, Kleinman JC. Decreased risk of stroke among postmenopausal hormone users. Results from a national cohort. Arch. Intern. Med. 153(1), 73-79 (1993).
43. Paganini-Hill A, Ross RK, Henderson BE. Postmenopausal oestrogen treatment and stroke: a prospective study. BMJ 297(6647), 519-522 (1988).
44. Grady D, Wenger NK, Herrington D et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/Progestin Replacement Study. Ann. Intern. Med. 132(9), 689-696 (2000).
45. Simon JA, Hsia J, Cauley JA et al. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-Progestin Replacement Study (HERS). Circulation 103(5), 638-642 (2001).
46. Wassertheil-Smoller S, Hendrix SL, Limacher M et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 289(20), 2673-2684 (2003).
47. Rossouw JE, Prentice RL, Manson JE et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297(13), 1465-1477 (2007).
48. Sare GM, Gray LJ, Bath PM. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur. Heart J. 29(16), 2031-2041 (2008).
49. Bath PM, Gray LJ. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ 330(7487), 342 (2005).
50. Renoux C, Dell'Aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 340, c2519 (2010).
51. Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J. Thromb. Haemost. 8(5), 979-986 (2010).
52. Moreau KL, Hildreth KL, Meditz AL, Deane KD, Kohrt WM. Endothelial function is impaired across the stages of the menopause transition in healthy women. J. Clin. Endocrinol. Metab. 97(12), 4692-4700 (2012).
53. Vitale C, Mercuro G, Cerquetani E et al. Time since menopause influences the acute and chronic effect of estrogens on endothelial function. Arterioscler. Thromb. Vasc. Biol. 28(2), 348-352 (2008).
54. Clarkson TB, Anthony MS, Morgan TM. Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens. J. Clin. Endocrinol. Metab. 86(1), 41-47 (2001).
55. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J. Womens Health (Larchmt) 15(1), 35-44 (2006).
56. Hsia J, Langer RD, Manson JE et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch. Intern. Med. 166(3), 357-365 (2006).
57. Schierbeck LL, Rejnmark L, Tofteng CL et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 345, e6409 (2012).
58. Miller VM, Black DM, Brinton EA et al. Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J. Cardiovasc. Transl. Res. 2(3), 228-239 (2009).
59. Grandas OH, Mountain DH, Kirkpatrick SS et al. Regulation of vascular smooth muscle cell expression and function of matrix metalloproteinases is mediated by estrogen and progesterone exposure. J. Vasc. Surg. 49(1), 185-191 (2009).
60. Zhan E, Keimig T, Xu J et al. Dose-dependent cardiac effect of oestrogen replacement in mice post-myocardial infarction. Exp. Physiol. 93(8), 982-993 (2008).
61. Smith NL, Heckbert SR, Lemaitre RN et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 292(13), 1581-1587 (2004).
62. Lemaitre RN, Weiss NS, Smith NL et al. Esterified estrogen and conjugated equine estrogen and the risk of incident myocardial infarction and stroke. Arch. Intern. Med. 166(4), 399-404 (2006).
63. Lokkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger C, Lidegaard O. Hormone therapy and risk of myocardial infarction: a national register study. Eur. Heart J. 29(21), 2660-2668 (2008).
64. Hemelaar M, Van Der Mooren MJ, Rad M, Kluft C, Kenemans P. Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review. Fertil. Steril. 90(3), 642-672 (2008).
65. Ho JY, Chen MJ, Sheu WH et al. Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women. Hum. Reprod. 21(10), 2715-2720 (2006).
66. Sumino H, Ichikawa S, Kasama S et al. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women. Atherosclerosis 189(2), 436-442 (2006).
67. Australian Institute of Health and Welfare. Australia's Health 2010. Australia's Health Series no. 12. Cat. no. AUS 122. Australian Institute of Health and Welfare, Canberra, Australia (2010).
68. Tsai SA, Stefanick ML, Stafford RS. Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009. Menopause 18(4), 385-392 (2011).
69. WHO. Cardiovascular diseases. Facts Sheet Edition N 137 (2012). www.who.int/mediacentre/factsheets/fs317/en/index.html (Accessed 14 December 2012
70. Hormone therapy has many favorable effects in newly menopausal women: initial findings of the Kronos Early Estrogen Prevention Study (KEEPS). News press release (2012). www.keepstudy.org/news/pr-100312-a.cfm (Accessed 4 April 2013
71. ELITE: Early Versus Late Intervention Trial With Estradiol. http://clinicaltrials.gov/ct2/show/NCT00114517 (Accessed 4 April 2013